Journals / MN Oftalmoloji / 2012 / Cilt: 19 - Sayı: 1

Comparing the efficacy and safety of topical cyclosporine A 0.05 % with artificial tears treatment in mild and moderate dry eye patients

Hafif ve orta şiddetteki kuru göz hastalarında topikal %0,05 siklosporin A’nın etkinliğinin ve güvenilirliğinin suni göz yaşı ile karşılaştırılması

Pages
41–46
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although there was a statistically significant increase in Schirmer test, tear break up time and ocular surface staining values in both eyes of patients that used topical cyclosporine A 0.05% and artificial tears, but there was no statistically significant difference between topical cyclosporine A 0.05% and artificial tears.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To compare the efficacy and safety of topical cyclosporine A 0.05% with artificial tears treatment in mild and moderate dry eye patients.
📊
Key Findings & Data:Materyal and Method: A total of 40 eyes of the 20 patients, 12 female and 8 male, with a mean age of 40±12.3 (range,43-62) years were included in this prospective study.
💡
Conclusion & Impact:Conclusion: Although there was a statistically significant increase in Schirmer test, tear break up time and ocular surface staining values in both eyes of patients that used topical cyclosporine A 0.05% and artificial tears, but there was no statistically significant difference between topical cyclosporine A 0.05% and artificial tears.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To compare the efficacy and safety of topical cyclosporine A 0.05% with artificial tears treatment in mild and moderate dry eye patients. Materyal and Method: A total of 40 eyes of the 20 patients, 12 female and 8 male, with a mean age of 40±12.3 (range,43-62) years were included in this prospective study. Topical cyclosporine A, 0.05 % was used twice a day for one eye and preservative free artificial tear drops four times a day for the other eye. Patients were evaluated using Schirmer testing, tear break up time, ocular surface staining for an average 5.7 months at 1.week,1 months, 3 months and 6. months. Results: Mean Schirmer test values increased from 6.9±2.4 mm/5 min to 11.3±2.9 mm/5 min and mean tear break up time from 3.8±2.9 sec to 6.4±3.6 sec; mean ocular surface staining values decreased from grade 1.1± 0.8 to 0.3±0.4 in topical cyclosporine A 0.05 % group. In preservative free artificial tears groups mean Schirmer test values increased from 7,4±2.3 mm/5 min to 11.3±2.9 mm/5 min and mean tear break up time from 3.9±1.6 sec to 6.3±3.8 sec; mean ocular surface staining values decreased from grade 0.8±0.8 to 0.2±0.4. Conclusion: Although there was a statistically significant increase in Schirmer test, tear break up time and ocular surface staining values in both eyes of patients that used topical cyclosporine A 0.05% and artificial tears, but there was no statistically significant difference between topical cyclosporine A 0.05% and artificial tears.

Özet

Amaç: Hafif ve orta şiddetteki kuru göz hastalarında topikal %0,05 siklosporin A’nın etkinlik ve güvenilirliğinin suni gözyaşı ile karşılaştırılması. Gereç ve Yöntem: Bu prospektif çalışmaya yaş ortalaması 40±12,3 (43-62 yaş) olan 12’si kadın, 8’i erkek toplam 20 hastanın 40 gözü dahil edildi. Hastaların bir gözüne topikal %0,05 siklosporin A günde 2 kez bir damla, diğerine ise koruyucu içermeyen suni gözyaşı günde 4 kez bir damla şeklinde başlandı. Tedavinin 1. haftası, 1., 3. ve 6. aylarında Schirmer testi, göz yaşı kırılma zamanı ve oküler yüzey boyanmasına göre değerlendirilen hastaların ortalama takip süresi 5.7 ay idi. Bulgular: Topikal %0,05 siklosporin A’nın kullanıldığı grupta Schirmer testi ortalama değeri 6,9±2,4 mm/5 dk’dan 11,3±2,9 mm/5 dk’ya, ortalama göz yaşı kırılma zamanı değerleri 3,8±2,9 sn’den 6,4±3,6 sn’ye çıkmış, ortalama oküler yüzey boyanması ise evre 1,1±0,8’den 0,3±0,4’e düşmüştür. Suni gözyaşı kullanılan grupta ise Schirmer testi 7,4±2,3 mm/5 dk’dan 9,0±2,1 mm/5 dk’ya, göz yaşı kırılma zamanı 3,9±1,6 sn’den 6,3±3,8 sn’ye çıkmış ve oküler yüzey boyanması da evre 0,8±0,8’den 0,2±0,4’e düşmüştür. Sonuç: Topikal %0,05 siklosporin A ve suni gözyaşı kullanılan gözlerin her ikisinde de Schirmer testi, göz yaşı kırılma zamanı ve oküler yüzey boyanma parametrelerinde istatistiksel anlamlı artış bulunmasına karşın gruplar arasında istatistiksel anlamlı fark bulunamamıştır

🔖

Cite This Article

MUSAOĞLU, M., YAZICIOĞLU, T., SEFER, A. G., ÖZERTÜRK, Y. (2012). Comparing the efficacy and safety of topical cyclosporine A 0.05 % with artificial tears treatment in mild and moderate dry eye patients. MN Oftalmoloji, Cilt: 19 - Sayı: 1, 41–46. https://ajindex.com/articles/295744

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kathleen S Kunert; Tisdale As; Gipson IK. Goblet Cell Numbers and Epithelial Proliferation In the Conjunctiva Of Patients With Dry Eye Syndrome Treated With Cyclosporine. Arch Opthalmol 2002;120:330-7
  2. Bilgin Közer L.[Dry Eye].In: O’dwyer Aydın P, Akova Aydın Y,Temel Göz Hastalıkları. 2st ed. Ankara: Güneş Tıp Kitapevleri 2011.p.183-91
  3. Henry D. Perry, MD; Renée Solomon,MD; Eric D. Donnenfeld, MD; Alicia R. Perry,BA; John R. Wittpenn, MD; Herb E. Greenman, MD et al. Evaluation of Topical Cyclosporine for the Treatment of Dry Eye Disease. Arc Ophthalmol 2008;126:1046-50
  4. Steven E, Wilson MD, Henry D. Perry. Long Term Resolition of Chronic Dry Eye Symptoms and Signs after Topical Cyclosporine Treatment. Opthalmology 2007;114:76-9
  5. Sall K, Stevenson OD, Mundrof TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine opthalmic emulsion in moderate to severe dry eye disease. Opthalmology 2000;107:631-9
  6. Stephen C; Pflugfelder MD; Abraham Solomon MD;Michael E Stern Ph.D.The Diagnosis and Management of Dry Eye. Cornea 2000;19:644-9
  7. Lelli GJ Jr, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006;25:635-8
  8. Okumus S, Erbagcı İ, Kocluk Y, Tasdemir S, Tatar G. Topical Cyclosporine in the Treatment of Thyroid Related Dry Eye Syndrome. T Klin J Ophthalmol 2011;20:73-8
  9. Sahli E, Hoşal BM, Gülbahçe R, Ustün H. The Effect of Topical Cyclosporine A on Clinical Findings and Cytological Grade of the Disease in Patients with Dry Eye. Cornea 2010; 12:1412-6
  10. Perry HD, Doshi-Cornevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH: Efficacy of Commercially Available Topical Cyclosporine A %0.05 In The Treatment of Meibomian Gland Dysfunction. Cornea 2006;25:171-5
  11. Mohammad HD, Pedram H. and Reza D. High-frequency Topical Cyclosporine 0.05 % in the Treatment of Severe Dry Eye Refractory to Twice-daily Regimen. Cornea 2009; 28:1091-6
  12. Stevenson D, Tauber, Reis BL. The Cyclosporin. A Phase II Study Group Efficacy and Safety of Cyclosporine Opthalmic Emulsion In The Treatment of Moderate to Severe Dry Eye Disease A Dose-Ranging Randomized Trial Opthalmology 2000;107:967-74
  13. Doğu B, Elibol O, Altıntaş Ö,Karadağ S. Çağlar Y. Kuru Göz Tedavisinde Topikal Siklosporinin Katkısı MN Oftalmol 2008;15:5-9 14. Small DS, Acheampog A, Reis B, Stern K, Stewart W, Berdy G et al. Blood Concentrations of Cyclosporine a During Longterm treatment with Cyclosporin a